Therapeutic effect of tolvaptan on chronic heart failure / 心血管康复医学杂志

ABSTRACT

Objective: To explore therapeutic effect of tolvaptan on chronic heart failure (CHF).Methods: A total of 102 CHF patients hospitalized in our hospital from Jun 2015 to Jun 2016 were selected.According to random number table, patients were divided into furosemide control group (n=52, received furosemide based on routine treatment) and tolvaptan group (n=50, received tolvaptan based on routine treatment).Cardiac output (CO), cardiac index (CI), stroke volume (SV), systemic vascular resistance (SVR) and therapeutic effect were observed and compared between two groups before and after treatment.Results: Compared with before treatment, there were significant rise in CO, CI and SV, and significant reduction in SVR in both groups after treatment, P<0.01 all;compared with furosemide control group after treatment, there were significant rise in CO [(4.41±0.71) L/min vs.(4.80±0.77) L/min], CI [(3.21±0.52) L·min-1·m-2 vs.(3.62±0.78) L·min-1·m-2] and SV [(70.09±14.90)ml vs.(79.60±13.10)ml], and significant reduction in SVR [(3111.30±931.85) dyne·s/cm5 vs.(2756.68±856.32) dyne·s/cm5] in tolvaptan group, P<0.05 or <0.01.Total effective rate of tolvaptan group was significantly higher than that of routine treatment (100.0% vs.75.0%), P=0.001.Conclusion: Tolvaptan can significantly improve heart function in patients with chronic heart failure,its therapeutic effect is significant, so it's worth extending.